Pharmacovigilance
| Product | Date | Safety information | Attachments |
|---|---|---|---|
| AVASTIN® - Bevacizumab |
Cases of Necrotizing Fasciitis Reported with AVASTIN |
||
| MabThera® - Rituximab |
Risk of Toxic Epidermal Necrolysis And Stevens-Johnson-Syndrome |
||
| SPRYCEL® - Dasatinib |
Risk of (PAH) Pulmonary Arterial Hypertension |
||
| Valdoxan® - Agomelatine |
Risk of hepatotoxicity with agomelatine |
||
| Arava® - leflunomide |
Risk of hepatotoxicity Risk of serious birth defects |
||
| Wellbutrin®/Zyban® - bupropion |
Increased risk of congenital cardiovascular malformations |
||
| Gilenya® - fingolimod |
Cardiovascular adverse events after the first dose of Gilenya® |
||
| Zofran® - ondansetron |
Risk of developing abnormal changes in the electrical activity of the heart |
||
| Avastin® - bevacizumab |
Reports of severe infectious endophthalmitis following unapproved intravitreal injection use |
||
| Actos® - pioglitazone |
Risk of bladder cancer |
